Clinical Trial Update: SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety of ixazomib targeting plasma cells in relapsing-remitting and progressive multiple sclerosis; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Queen Mary University of London | Conditions: Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 | Status: RECRUITING